Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Other financing activities (2017 - 2025)

Historic Other financing activities for Sutro Biopharma (STRO) over the last 9 years, with Q3 2025 value amounting to $25000.0.

  • Sutro Biopharma's Other financing activities fell 6621.62% to $25000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $290000.0, marking a year-over-year decrease of 4020.62%. This contributed to the annual value of $509000.0 for FY2024, which is 9962.63% down from last year.
  • Sutro Biopharma's Other financing activities amounted to $25000.0 in Q3 2025, which was down 6621.62% from $61000.0 recorded in Q2 2025.
  • Sutro Biopharma's Other financing activities' 5-year high stood at $580000.0 during Q3 2021, with a 5-year trough of -$84000.0 in Q4 2021.
  • Its 5-year average for Other financing activities is $159705.9, with a median of $61000.0 in 2025.
  • Per our database at Business Quant, Sutro Biopharma's Other financing activities tumbled by 9137.93% in 2022 and then surged by 51666.67% in 2024.
  • Over the past 5 years, Sutro Biopharma's Other financing activities (Quarter) stood at -$84000.0 in 2021, then surged by 159.52% to $50000.0 in 2022, then crashed by 34.0% to $33000.0 in 2023, then decreased by 27.27% to $24000.0 in 2024, then rose by 4.17% to $25000.0 in 2025.
  • Its Other financing activities stands at $25000.0 for Q3 2025, versus $61000.0 for Q2 2025 and $180000.0 for Q1 2025.